A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development

Biochemical Pharmacology

Volumn 78, Issue 4, 2009, Pages 315-325

  Zhao, Lei ^a   Jin, Weijun ^b   Rader, Daniel ^c   Packard, Chris ^d   Feuerstein, Giora ^a  

^a PFIZER INC   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CETP; HDL; Torcetrapib, Atherosclerosis; Translational Medicine

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; BEZAFIBRATE; BIOLOGICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; COLESTIPOL; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MOPERONE; NICOTINIC ACID; PLACEBO; TORCETRAPIB;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CASE STUDY; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG PROGRAM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EVIDENCE BASED PRACTICE; GENOTYPE; HUMAN; HYPERTENSION; IMAGE ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RISK FACTOR; RISK REDUCTION; STRUCTURE ANALYSIS; TREATMENT DURATION; VALIDATION PROCESS;

EID: 67349279795     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.014     Document Type: Note

References (75)

1. Jones P.H., Farmer J.A., Cressman M.D., McKenney J.M., Wright J.T., Proctor J.D., et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 14 (1991) 146-151
2. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15 (1995) 678-682
3. Gagne C., Gaudet D., and Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105 (2002) 2469-2475
4. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62 (1977) 707-714
5. Linsel-Nitschke P., and Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4 (2005) 193-205
6. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
7. Morehouse L.A., Sugarman E.D., Bourassa P.A., Sand T.M., Zimetti F., Gao F., et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48 (2007) 1263-1272
8. Packard C.J., Ford I., Robertson M., Shepherd J., Blauw G.J., Murphy M.B., et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112 (2005) 3058-3065
9. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 290 (2003) 2292-2300
10. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 297 (2007) 1675-1682
11. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
12. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
13. Blankenhorn D.H., Johnson R.L., Nessim S.A., Azen S.P., Sanmarco M.E., and Selzer R.H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 8 (1987) 356-387
14. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., and Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. a 4-year follow-up. J Am Med Assoc 264 (1990) 3013-3017
15. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., and Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc 264 (1990) 3007-3012
16. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
17. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
18. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
19. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
20. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96 (1997) 2137-2143
21. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., and de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
22. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.
23. Tangirala R.K., Tsukamoto K., Chun S.H., Usher D., Pure E., and Rader D.J. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100 (1999) 1816-1822
24. Nicholls S.J., Cutri B., Worthley S.G., Kee P., Rye K.A., Bao S., et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25 (2005) 2416-2421
25. Terasaka N., Yu S., Yvan-Charvet L., Wang N., Mzhavia N., Langlois R., et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 118 (2008) 3701-3713
26. Nobecourt E., Jacqueminet S., Hansel B., Chantepie S., Grimaldi A., Chapman M.J., et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48 (2005) 529-538
27. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., and Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 (2006) 504-511
28. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995) 1987-1994
29. Birjmohun R.S., van Leuven S.I., Levels J.H., van't Veer C., Kuivenhoven J.A., Meijers J.C., et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 27 (2007) 1153-1158
30. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (2005) 1543-1550
31. Packard C.J., and Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997) 3542-3556
32. Blanco-Vaca F., Escola-Gil J.C., Martin-Campos J.M., and Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 42 (2001) 1727-1739
33. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 15 (2005) 265-271
34. Asztalos B.F., Horvath K.V., Kajinami K., Nartsupha C., Cox C.E., Batista M., et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 45 (2004) 448-455
35. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164 (2002) 361-369
36. Brinton E.A., Eisenberg S., and Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14 (1994) 707-720
37. Welty F.K., Lichtenstein A.H., Lamon-Fava S., Schaefer E.J., and Marsh J.B. Effect of body mass index on apolipoprotein A-I kinetics in middle-aged men and postmenopausal women. Metabolism 56 (2007) 910-914
38. Ooi E.M., Watts G.F., Farvid M.S., Chan D.C., Allen M.C., Zilko S.R., et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 13 (2005) 1008-1016
39. Shepherd J., Packard C.J., Patsch J.R., Gotto Jr. A.M., and Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63 (1979) 858-867
40. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
41. Orloff D.G. Regulatory considerations in the development of high-density lipoprotein therapies. Am J Cardiol 100 (2007) n10-n14
42. van der Steeg W.A., Holme I., Boekholdt S.M., Larsen M.L., Lindahl C., Stroes E.S., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51 (2008) 634-642
43. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.E., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
44. Brown M.L., Inazu A., Hesler C.B., Agellon L.B., Mann C., Whitlock M.E., et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342 (1989) 448-451
45. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323 (1990) 1234-1238
46. Wang X., and Paigen B. Genome-wide search for new genes controlling plasma lipid concentrations in mice and humans. Curr Opin Lipidol 16 (2005) 127-137
47. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
48. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res 34 (1993) 1255-1274
49. Matsuura F., Wang N., Chen W., Jiang X.C., and Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 116 (2006) 1435-1442
50. Rye K.A., and Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24 (2004) 421-428
51. Tall A.R. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356 (2007) 1364-1366
52. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., and Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19 (1999) 1105-1110
53. Westerterp M., van der Hoogt C.C., de Haan W., Offerman E.H., Dallinga-Thie G.M., Jukema J.W., et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2552-2559
54. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., and Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364 (1993) 73-75
55. Van Eck M., Ye D., Hildebrand R.B., Kar Kruijt J., de Haan W., Hoekstra M., et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 100 (2007) 678-685
56. Herrera V.L., Makrides S.C., Xie H.X., Adari H., Krauss R.M., Ryan U.S., et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 5 (1999) 1383-1389
57. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2106-2112
58. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 274 (1999) 36912-36920
59. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 96 (1995) 2071-2074
60. Cazita P.M., Berti J.A., Aoki C., Gidlund M., Harada L.M., Nunes V.S., et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res 44 (2003) 33-40
61. de Grooth G.J., Klerkx A.H., Stroes E.S., Stalenhoef A.F., Kastelein J.J., and Kuivenhoven J.A. A review of CETP and its relation to atherosclerosis. J Lipid Res 45 (2004) 1967-1974
62. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
63. Nissen S.E., Tardif J.C., Nicholls S.J., Revkin J.H., Shear C.L., Duggan W.T., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
64. Nicholls S.J., Tuzcu E.M., Brennan D.M., Tardif J.C., and Nissen S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118 (2008) 2506-2514
65. Kastelein J.J., van Leuven S.I., Burgess L., Evans G.W., Kuivenhoven J.A., Barter P.J., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
66. Bots M.L., Visseren F.L., Evans G.W., Riley W.A., Revkin J.H., Tegeler C.H., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
67. Vergeer M., Bots M.L., van Leuven S.I., Basart D.C., Sijbrands E.J., Evans G.W., et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 (2008) 2515-2522
68. Clark R.W., Ruggeri R.B., Cunningham D., and Bamberger M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47 (2006) 537-552
69. Forrest M.J., Bloomfield D., Briscoe R.J., Brown P.N., Cumiskey A.M., Ehrhart J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154 (2008) 1465-1473
70. Feuerstein G.Z., Rutkowski L.J., Walsh F.S., Stiles G.L., and Ruffolo R.R. The role of Translational Medicine and biomarker research in drug discovery and development. Am Drug Discovery (2007) 23-28
71. Yvan-Charvet L., Ranalletta M., Wang N., Han S., Terasaka N., Li R., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 117 (2007) 3900-3908
72. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., Trip M.D., et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95 (2005) 1085-1088
73. Krishna R., Anderson M.S., Bergman A.J., Jin B., Fallon M., Cote J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370 (2007) 1907-1914
74. Connell J.M., and Davies E. The new biology of aldosterone. J Endocrinol 186 (2005) 1-20
75. Serruys P.W., Garcia-Garcia H.M., Buszman P., Erne P., Verheye S., Aschermann M., et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118 (2008) 1172-1182